Ligand Enters into Licensing Deal with venBio Partners

Ligand Pharmaceuticals Incorporated

Represented Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) in connection with an OmniAb platform license agreement with venBio Partners, a venture capital group that focuses its investments in potential first and best in-class therapeutic product applications. Pursuant to the license, venBio portfolio companies will have access to the full OmniAb platform to discover fully human mono and bispecific antibodies. Read the press release.

Ligand is a biopharmaceutical company that focuses on developing and/or acquiring technologies that help pharmaceutical companies in discovering and creating medicines.

San Diego-based Hayden Trubitt represented Ligand Pharmaceuticals in this transaction.